Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GU-228: Mycophenolate Mofetil in Combination With Prednisone as First-line Treatment of Immune Related Hepatitis Resulting From Checkpoint Inhibitor Therapy

NCT07663422 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT07663422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07663422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GU-228: Mycophenolate Mofetil in Combination With Prednisone as First-line Treatment of Immune Related Hepatitis Resulting From Checkpoint Inhibitor Therapy
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
July 23, 2026
Completion date
September 30, 2028
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune-mediated hepatitis, immune-related adverse event